Tempus expands multi-year collaboration on intismeran with Moderna, Merck
Tempus announced an expanded, multi-year collaboration to support potential commercialization of intismeran autogene (V940/mRNA-4157), a novel individualized neoantigen therapy, evaluated in combination with Keytruda (pembrolizumab).